Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Q&A
  • About Us
    • Our Coverage
    • Team

Genmab

1,843.00 DKK

+2.65 %

Less than 1K followers

GMAB

NASDAQ Copenhagen

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Valuation
Income statement
Quarter data

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Genmab

2019202020212022202320242025
Revenue5,366.010,111.08,482.014,595.016,474.021,526.023,653.5
growth-%88.4 %-16.1 %72.1 %12.9 %30.7 %9.9 %
EBITDA2,638.06,313.03,018.06,357.05,321.07,116.07,426.7
EBIT2,638.06,313.03,018.06,357.05,321.06,703.06,771.8
Profit before taxes2,859.05,904.03,983.07,035.05,637.09,164.07,655.6
Net income2,166.04,758.03,008.05,522.04,352.07,844.06,123.2
EPS33.3473.2446.3084.4566.64122.2198.56
Dividend0.000.000.000.000.000.000.00
Dividend ratio0.0 %0.0 %0.0 %0.0 %0.0 %0.0 %0.0 %

Profitability and return on capital

2019202020212022202320242025
EBITDA-%49.2 %62.4 %35.6 %43.6 %32.3 %33.1 %31.4 %
EBIT-%49.2 %62.4 %35.6 %43.6 %32.3 %31.1 %28.6 %
ROE15.4 %24.9 %13.6 %20.1 %13.8 %21.4 %16.5 %
ROI14.3 %22.5 %12.2 %18.2 %12.3 %17.1 %7.5 %
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.